Abstract PR11: Allogeneic memory-like natural killer (NK) cell therapy with IL-15 superagonist with or without ipilimumab for advanced, incurable head and neck cancer: A phase 1 trial
Bibliographic record
Abstract
Abstract Purpose: Patients with recurrent incurable, or metastatic (R/M) head and neck cancers (HNCs) refractory to platinum and immunotherapy have poor survival. Cellular therapies have emerged as treatments with potential activity in solid tumors. This proof-of-concept trial investigated an allogeneic cytokine-induced, memory-like (CIML) NK cell infusion followed by IL-15 superagonist (sa) after lead-in CTLA-4 inhibition (ipilimumab) plus lymphodepleting (LD) chemotherapy in advanced HNC. Methods: This phase 1 single-center trial enrolled patients (pts) with R/M HNC (n=7 HNSCC, n=3 salivary cancer) regardless of human papillomavirus (HPV) status who had prior platinum and immunotherapy. Pts in cohort 1 received LD fludarabine (25 mg/m2) and cyclophosphamide (60 mg/m2/kg) on days -6 to -2 prior to haploidentical CIML NK cell infusion on day 0 (5-10 × 106 viable cells/kg=dose level 0) followed by N-803 (IL-15sa, 15 mcg/kg subcutaneously) starting on day +1 every 21-days for 4-doses; in cohort 2, pts received the same regimen with a dose of lead-in ipilimumab on day -7. Cohort 1 treated 3 pts at dose level 0; <2 DLTs triggered an additional 3 pts (n=6). Cohort 2 treated an additional 4 pts. Primary objective: safety, maximum tolerated dose of CIML NK cells. Secondary objectives: objective response rate, progression-free survival (PFS), overall survival (OS), and phenotypic expansion and function of adoptively transferred NK cells. Results: From 9/8/20 to 12/2/22, 10 pts enrolled. One DLT was observed at dose level 0. Median age: 58; 9/10 (90%) were men; 8 (80%) had oropharyngeal primaries (6 HPV+) with a median 6 prior lines of therapy for R/M disease (range: 3-8). Eight (80%) had offspring donors. Grade (G) 3-4 hematologic adverse events were common (10/10, 100%). One patient died of G5 febrile neutropenia and infection (DLT). Median days hospitalized: 15 (range: 9-37). Mild CRS was observed in 6/10 (60%); 5/6 received anti-IL6 therapy; no neurotoxicity was observed. One (10%) partial response (PR) lasted 6.5 months; 6 (60%) had stable disease, 3 (30%) had progression. Tumor regression was observed in 5/10 (50%) at day +30. At a median follow-up of 20.2 mos, median PFS: 2.6 mos (95%CI 1-3.9); median OS: 3.5 mos (95%CI 1-4.7). CIML NK expansion in the peripheral blood (PB) occurred on day +7 in 9/10 of pts. A donor-specific antibody was found in the one patient without expansion. In pts with tumor regression at day +30 compared to those without, CD56dimCD16+ NK cell clusters expanded by day +14 (93.7% vs. 37.3% of PB NK cells). The CD16+KIR+CD57+ NK cell cluster was more prevalent in the ipilimumab-treated pts at the time of tumor regression (16% vs. 4%, p<0.05). Conclusion: Allogeneic CIML NK cells can induce tumor regression associated with persistent CIML NK cell expansion in advanced HNC pts. Tumor regression was associated with CD56dimCD16+ NK cell expansion. We demonstrate safety and feasibility with the expected toxicity of LD. These findings have important implications for the development of cellular therapies in solid tumors. Citation Format: Glenn J. Hanna, Roman M. Shapiro, Michal Sheffer, Michela Ansuinelli, Grace Birch, Robert A. Redd, Alejandro Alonso, Denbaa Bat-Erdene, Samantha Himberg, Heather Daley, Diego E. Hernandez-Rodriquez, Katharin L. Shaw, Jerome Ritz, Sarah Nikiforow, Robert J. Soiffer, Rizwan Romee. Allogeneic memory-like natural killer (NK) cell therapy with IL-15 superagonist with or without ipilimumab for advanced, incurable head and neck cancer: A phase 1 trial [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PR11.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".